Tests an oncolytic virus injected into recurrent glioblastoma brain tumors
Tests an oncolytic virus injected into the tumor in adults with recurrent glioblastoma.
Plain-language title generated from the registry record
Registry title: Clinical Study of Oncolytic Virus in Glioblastoma
Key facts
- Where
- Mianyang, ChinaSee the site
- Phase
- Phase 1/2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with recurrent glioblastoma, a brain tumor that has come back, where standard treatment is considered ineffective. The oncolytic virus is injected into the tumor.
- Age
- 18 to 70 years
- Sex
- All sexes can join.
- Disease stage
- Recurrent glioblastoma confirmed by tissue examination. On MRI, the largest recurrent lesion is greater than 1.0 cm (0.4 in) across. Standard treatments are considered ineffective.
- Earlier treatment
- More than 28 days since the last radiotherapy or surgery. Steroid dose stable or falling for at least 7 days. Time since last antitumor drug: vincristine 2 weeks, nitrosoureas 4 weeks, bevacizumab 4 weeks, temozolomide 6 weeks. Cannot have had gene transfer therapy or any oncolytic virus before.
Main reasons for not taking part
- Tumor spread outside the brain (extracranial metastases)
- Pregnant or breastfeeding
- Active infection, immunodeficiency, autoimmune disease, or active HBV, HCV or HIV infection
- Use of blood thinners or other drugs that raise bleeding risk
- Unable to have MRI, for example because of a pacemaker or metal implants
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Source: NCT07145047, who can take part
Where in China
- Mianyang Central HospitalMianyang, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Mianyang Central Hospital
- Trial code
- NCT07145047
- Record updated
- 19 December 2025
- Original description
This clinical trial aims to evaluate whether an oncolytic viral agent can treat recurrent glioblastoma. It will also assess the safety and tolerability of the oncolytic viral agent. The primary question it seeks to answer is: What medical problems do participants experience when injected with the oncolytic viral agent? Researchers will administer the oncolytic viral agent via intratumoral injection to determine its efficacy in treating recurrent glioblastoma.Read full original descriptionShow less
Clinical Study on the Application of Oncolytic Virus in Recurrent Glioblastoma
This clinical trial aims to evaluate whether an oncolytic viral agent can treat recurrent glioblastoma. It will also assess the safety and tolerability of the oncolytic viral agent. The primary question it seeks to answer is: What medical problems do participants experience when injected with the oncolytic viral agent? Researchers will administer the oncolytic viral agent via intratumoral injection to determine its efficacy in treating recurrent glioblastoma.
Participant Procedures:
Receive the initial injection, followed by additional injections every 2-4 weeks for a total of 6 injections.
Undergo physical examinations and tests every 2 to 4 weeks. Record their symptoms, hematological test results, and imaging findings.
Inclusion: Patients with recurrent glioblastoma, for whom the standard methods of treatment are considered ineffective by the medical commission; Histologically confirmed recurrent glioblastoma; Magnetic resonance imaging (MRI) showed that the maximum diameter of recurrent lesions is greater than 1.0 cm; Before inclusion of patients in the study, at least one of the following types of therapy was previously performed: 4.1 Time from the last radiotherapy/surgery is more than 28 days; 4.2 Subjects maintained stable or declining for at least 7 days prior to corticosteroid regimen; 4.3 Most recent antitumor therapy must have been completed within the specified time prior to treatment: vincristine 2 weeks, nitrosoureas 4 weeks, bevacizumab 4 weeks, temozolomide 6 weeks; Age >=18 years, <=70 years; Hematological indicators, kidney and liver function are normal; The subjects must agree to the use of an acceptable contraceptive method throughout the study, from the time informed consent is provided to 180 days after receiving treatment; Patient's ability to perform the study procedure and provide written informed consent in accordance with the GCP and local laws.
Exclusion: Participated in other drug clinical trials within 4 weeks; Uncontrolled active infection, unstable or severe concomitant disease of infection. Patients with immunodeficiency, autoimmune diseases, active HBV infection, HCV infection, or active HIV infection; Subjects are receiving immunosuppressive therapy, or concurrent chemotherapy, or radiation, or biotherapy; There are prohibited items for MRI, such as: pacemakers, epicardial pacemaker wires, infusion pumps, surgical and/or aneurysm clips, shrapnel, metal prostheses, potentially magnetic implants, metal objects in the eye, etc; Vaccination within 30 days prior to administration; Patients who have received gene transfer therapy or treated with any type of oncolytic virus; In the investigator's judgment, there is a serious concomitant disease that endangers the patient's safety or interferes with the patient's ability to complete the study; Preoperative bleeding susceptibility or use of anticoagulants or any medication that may increase the risk of bleeding; Patients with a history of psychotropic substance abuse who are unable to quit or with mental disorders; Subjects had any active autoimmune disease or a history of autoimmune disease; Has a history of antiviral drug use within 1 week; History of substance abuse or known medical, or psychological, or social conditions, such as alcohol or drug abuse; Allergic, hypersensitive or intolerant to study oncolytic viruses (including any excipients); History of encephalitis, or multiple sclerosis, or other central nervous system (CNS) infections, or primary CNS disease; Have poorly controlled clinical diseases, such as liver aminotransferase (aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT)) or total bilirubin > 2 times the upper normal limit; Incompatibility of patients with the inclusion criteria mentioned above; Patients with extracranial metastases; Female subjects: during pregnancy or lactation; Male or female patients who refused contraception during the study period and for 6 months after dosing.